| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NNMT |
| Uniprot No | P40261 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-264aa |
| 氨基酸序列 | MESGFTSKDTYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFC LDGVKGDLLIDIGSGPTIYQLLSACESFKEIVVTDYSDQNLQELEKWLKK EPEAFDWSPVVTYVCDLEGNRVKGPEKEEKLRQAVKQVLKCDVTQSQPLG AVPLPPADCVLSTLCLDAACPDLPTYCRALRNLGSLLKPGGFLVIMDALK SSYYMIGEQKFSSLPLGREAVEAAVKEAGYTIEWFEVISQSYSSTMANNE GLFSLVARKLSRPL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NNMT(烟酰胺N-甲基转移酶)重组蛋白的模拟参考文献示例，供参考：
---
1. **文献名称**: *Expression and Functional Characterization of Recombinant Human NNMT: Role in Cellular Metabolism*
**作者**: Smith A, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组人源NNMT蛋白，验证其甲基转移酶活性。实验表明，重组NNMT可将烟酰胺转化为1-甲基烟酰胺，并影响细胞内的NAD+代谢水平，提示其在能量代谢调控中的潜在作用。
2. **文献名称**: *NNMT Overexpression Promotes Cancer Metastasis via Methylation-Dependent Metabolic Reprogramming*
**作者**: Li J, et al.
**摘要**: 通过重组NNMT蛋白的体外实验，发现NNMT过表达通过甲基化烟酰胺消耗SAM(S-腺苷甲硫氨酸)，导致肿瘤细胞内甲基化失衡和线粒体功能异常，进而促进肿瘤侵袭转移。
3. **文献名称**: *Structural Insights into NNMT Inhibition by Small Molecules: A Basis for Therapeutic Development*
**作者**: Kim S, et al.
**摘要**: 利用重组NNMT蛋白的晶体结构，筛选并鉴定出新型小分子抑制剂，阐明其与NNMT活性位点的结合机制。该研究为代谢性疾病和癌症的靶向治疗提供了理论依据。
4. **文献名称**: *Recombinant NNMT as a Potential Biomarker in Neurodegenerative Diseases*
**作者**: Garcia R, et al.
**摘要**: 通过分析阿尔茨海默病模型小鼠脑组织中重组NNMT的表达水平，发现其与神经炎症和氧化应激相关，提示NNMT可能作为神经退行性疾病的生物标志物或治疗靶点。
---
如需实际文献，建议通过 **PubMed/Google Scholar** 检索关键词：
`recombinant NNMT protein`, `NNMT overexpression`, `NNMT inhibitor`, `NNMT metabolic role`。
部分真实研究可参考期刊如 *Scientific Reports*、*Journal of Biological Chemistry* 等。
**Background of NNMT Recombinant Protein**
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the methylation of nicotinamide (vitamin B3) using S-adenosyl-L-methionine (SAM) as a methyl donor, producing S-adenosyl-L-homocysteine (SAH) and 1-methylnicotinamide (1-MNA). This reaction plays a critical role in cellular methylation processes, nicotinamide metabolism, and the regulation of SAM/SAH ratios, which influence epigenetic modifications and metabolic homeostasis. NNMT is predominantly expressed in the liver but is also found in adipose tissue, kidneys, and the brain.
Dysregulation of NNMT has been linked to various diseases, including metabolic disorders (e.g., obesity, diabetes), neurodegenerative conditions, and cancers. Overexpression of NNMT in tumors, for instance, is associated with altered energy metabolism, drug resistance, and poor prognosis, highlighting its potential as a therapeutic target. Conversely, reduced NNMT activity may contribute to metabolic syndrome or liver dysfunction.
Recombinant NNMT protein is produced using biotechnological platforms (e.g., E. coli, mammalian cells) to enable precise study of its structure, enzymatic activity, and interactions. Purified NNMT serves as a vital tool for in vitro assays, inhibitor screening, and mechanistic studies. Its recombinant form ensures consistency, scalability, and elimination of confounding factors from native tissues. Recent research also explores engineered NNMT variants to modulate substrate specificity or enhance stability for industrial or therapeutic applications.
Overall, NNMT recombinant protein bridges fundamental biochemistry with translational research, offering insights into metabolic pathways and opportunities for drug development targeting NNMT-related pathologies.
×
